Table I.
Patient characteristics.
| Parameter | Ovarian cancers | Benign diseases | Other cancers | Borderline tumors | BRCA1 mutations |
|---|---|---|---|---|---|
| Total, n | 162 | 342 | 33 | 23 | 59 |
| Age, years | |||||
| Mean | 59.7 | 40.7 | 57.5 | 46.3 | 47.6 |
| Range | 24–90 | 18–89 | 27–87 | 19–83 | 34–64 |
| Hormonal status, n | |||||
| Premenopausal | 38 | 256 | 10 | 11 | 39 |
| Postmenopausal | 124 | 86 | 23 | 12 | 20 |
| Ovarian cancer histopathology, n (%) | |||||
| Serous | 132 (81.5) | – | – | 16 (69.6) | – |
| Mucinous | 9 (5.6) | – | – | 6 (26.1) | – |
| Clear cell | 8 (4.9) | – | – | 0 (0.0) | – |
| Endometrioid | 13 (8.0) | – | – | 1 (4.3) | – |
| Ovarian cancer FIGO stage, n (%) | |||||
| I and II | 54 (33.3) | – | – | 22 (95.7) | – |
| III and IV | 108 (66.7) | – | – | 1 (4.3) | – |
| Ovarian cancer grade, n (%) | |||||
| 1 | 34 (21.0) | – | – | – | – |
| 2 | 54 (33.3) | – | – | – | – |
| 3 | 74 (45.7) | – | – | – | – |
| Benign tumor histopathology, n (%) | |||||
| Endometriosis | – | 121 (35.4) | – | – | – |
| Teratoma | – | 44 (12.9) | – | – | – |
| Serous cystadenoma | – | 22 (6.4) | – | – | – |
| Mucinous cystadenoma | – | 25 (7.3) | – | – | – |
| Cystadenofibroma | – | 21 (6.1) | – | – | – |
| Follicular cysts | – | 36 (10.5) | – | – | – |
| Paraovarian cysts | – | 26 (7.6) | – | – | – |
| Hemorrhagic cysts | – | 30 (8.8) | – | – | – |
| Inflammatory tumors | – | 13 (3.8) | – | – | – |
| Cirrhosis | – | 4 (1.2) | – | – | – |
BRCA1, breast cancer 1; -, not applicable; FIGO, International Federation of Gynecology and Obstetrics.